NCT01016093 - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions

Beta-ThalassemiaBone Marrow Transplantation

Interventions

DRUG

Zoledronic acid

Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.

DRUG

Placebo

Trial Locations (1)

14114

Hematology-Oncology & SCT Research Center, Tehran